Vaccination with Phosphoglycan-Deficient Leishmania major Protects Highly Susceptible Mice from Virulent Challenge without Inducing a Strong Th1 Response
Long-term immunity to Leishmania may require the continued presence of parasites, but previous attempts to create attenuated parasites that persist without causing disease have had limited success. Since Leishmania major mutants that lack lipophosphoglycan and other secreted phosphoglycans, termed l...
Gespeichert in:
Veröffentlicht in: | The Journal of immunology (1950) 2004-03, Vol.172 (6), p.3793-3797 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3797 |
---|---|
container_issue | 6 |
container_start_page | 3793 |
container_title | The Journal of immunology (1950) |
container_volume | 172 |
creator | Uzonna, Jude E Spath, Gerald F Beverley, Stephen M Scott, Phillip |
description | Long-term immunity to Leishmania may require the continued presence of parasites, but previous attempts to create attenuated parasites that persist without causing disease have had limited success. Since Leishmania major mutants that lack lipophosphoglycan and other secreted phosphoglycans, termed lpg2-, persist indefinitely in infected mice without inducing any disease, we tested their ability to provide protection to virulent L. major challenge. In response to leishmanial Ag stimulation, cells from lpg2--infected mice produced minimal levels of IL-4 and IL-10, as well as very low levels of IFN-gamma. Nevertheless, when BALB/c mice infected with lpg2- parasites were challenged with virulent L. major they were protected from disease. Thus, these findings report on attenuated parasites that may be used to induce long-term protection against leishmaniasis and indicate that the immunity induced can be maintained in the absence of a strong Th1 response. |
doi_str_mv | 10.4049/jimmunol.172.6.3793 |
format | Article |
fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_pasteur_03109128v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18035252</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-dadb7b96334b81cbd9a6c9d282430daa3b980ae61bb5d957421871158b25a3743</originalsourceid><addsrcrecordid>eNqFkcuO0zAUhi0EYjoDT4CEvIJVim-xk-WowHSkIkbMMFvLdtzGVRIH2yHqo_C2uLRcdqzOWXz_uegD4BVGS4ZY_W7v-n4afLfEgiz5koqaPgELXJao4Bzxp2CBECEFFlxcgMsY9wghjgh7Di5wiRDDFVuAH4_KGDeo5PwAZ5daeNf6OLZ-1x2MGor3duuMs0OCG-ti26vBKdirvQ_wLvhkTYpw7XZtd4D3UzR2TE53Fn5yxsJt8D18dGHqjvlVq7rc7OyvNX5K8HZoprx7BxW8T8Hn5qHF8IuNox-ifQGebVUX7ctzvQJfP354WK2Lzeeb29X1pjCMiVQ0qtFC15xSpitsdFMrbuqGVIRR1ChFdV0hZTnWumzqUjCCK4FxWWlSKioYvQLFaW6-T47B9SocpFdOrq83clQx2SlIRDGqMam-48y_OfFj8N8mG5PsXX6869Rg_RSlwAJxRvh_QVwhWpKSZJCeQBN8jMFu_5yBkTyqlr9Vy6xacnlUnVOvz-Mn3dvmb-bsNgNvz49lP7MLVsY-K8g4lvM8_zPqJ-QMtxI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18035252</pqid></control><display><type>article</type><title>Vaccination with Phosphoglycan-Deficient Leishmania major Protects Highly Susceptible Mice from Virulent Challenge without Inducing a Strong Th1 Response</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Uzonna, Jude E ; Spath, Gerald F ; Beverley, Stephen M ; Scott, Phillip</creator><creatorcontrib>Uzonna, Jude E ; Spath, Gerald F ; Beverley, Stephen M ; Scott, Phillip</creatorcontrib><description>Long-term immunity to Leishmania may require the continued presence of parasites, but previous attempts to create attenuated parasites that persist without causing disease have had limited success. Since Leishmania major mutants that lack lipophosphoglycan and other secreted phosphoglycans, termed lpg2-, persist indefinitely in infected mice without inducing any disease, we tested their ability to provide protection to virulent L. major challenge. In response to leishmanial Ag stimulation, cells from lpg2--infected mice produced minimal levels of IL-4 and IL-10, as well as very low levels of IFN-gamma. Nevertheless, when BALB/c mice infected with lpg2- parasites were challenged with virulent L. major they were protected from disease. Thus, these findings report on attenuated parasites that may be used to induce long-term protection against leishmaniasis and indicate that the immunity induced can be maintained in the absence of a strong Th1 response.</description><identifier>ISSN: 0022-1767</identifier><identifier>EISSN: 1550-6606</identifier><identifier>DOI: 10.4049/jimmunol.172.6.3793</identifier><identifier>PMID: 15004184</identifier><language>eng</language><publisher>United States: Am Assoc Immnol</publisher><subject>Animals ; Female ; Genetic Predisposition to Disease ; Glycosphingolipids ; Glycosphingolipids - deficiency ; Glycosphingolipids - genetics ; Immunity, Innate ; Immunity, Innate - genetics ; Interleukin-10 ; Interleukin-10 - antagonists & inhibitors ; Interleukin-10 - biosynthesis ; Interleukin-4 ; Interleukin-4 - antagonists & inhibitors ; Interleukin-4 - biosynthesis ; Leishmania major ; Leishmania major - genetics ; Leishmania major - immunology ; Leishmania major - pathogenicity ; Leishmaniasis, Cutaneous ; Leishmaniasis, Cutaneous - genetics ; Leishmaniasis, Cutaneous - immunology ; Leishmaniasis, Cutaneous - prevention & control ; Life Sciences ; Membrane Proteins ; Membrane Proteins - deficiency ; Membrane Proteins - genetics ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Mice, Knockout ; Mice, SCID ; Protozoan Proteins ; Protozoan Proteins - genetics ; Protozoan Vaccines ; Protozoan Vaccines - administration & dosage ; Protozoan Vaccines - genetics ; Protozoan Vaccines - immunology ; Th1 Cells ; Th1 Cells - immunology ; Th1 Cells - metabolism ; Th1 Cells - parasitology ; Vaccines, Attenuated ; Vaccines, Attenuated - administration & dosage ; Vaccines, Attenuated - genetics ; Vaccines, Attenuated - immunology ; Virulence ; Virulence - genetics ; Virulence - immunology</subject><ispartof>The Journal of immunology (1950), 2004-03, Vol.172 (6), p.3793-3797</ispartof><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-dadb7b96334b81cbd9a6c9d282430daa3b980ae61bb5d957421871158b25a3743</citedby><cites>FETCH-LOGICAL-c447t-dadb7b96334b81cbd9a6c9d282430daa3b980ae61bb5d957421871158b25a3743</cites><orcidid>0000-0002-0256-2029</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15004184$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://pasteur.hal.science/pasteur-03109128$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Uzonna, Jude E</creatorcontrib><creatorcontrib>Spath, Gerald F</creatorcontrib><creatorcontrib>Beverley, Stephen M</creatorcontrib><creatorcontrib>Scott, Phillip</creatorcontrib><title>Vaccination with Phosphoglycan-Deficient Leishmania major Protects Highly Susceptible Mice from Virulent Challenge without Inducing a Strong Th1 Response</title><title>The Journal of immunology (1950)</title><addtitle>J Immunol</addtitle><description>Long-term immunity to Leishmania may require the continued presence of parasites, but previous attempts to create attenuated parasites that persist without causing disease have had limited success. Since Leishmania major mutants that lack lipophosphoglycan and other secreted phosphoglycans, termed lpg2-, persist indefinitely in infected mice without inducing any disease, we tested their ability to provide protection to virulent L. major challenge. In response to leishmanial Ag stimulation, cells from lpg2--infected mice produced minimal levels of IL-4 and IL-10, as well as very low levels of IFN-gamma. Nevertheless, when BALB/c mice infected with lpg2- parasites were challenged with virulent L. major they were protected from disease. Thus, these findings report on attenuated parasites that may be used to induce long-term protection against leishmaniasis and indicate that the immunity induced can be maintained in the absence of a strong Th1 response.</description><subject>Animals</subject><subject>Female</subject><subject>Genetic Predisposition to Disease</subject><subject>Glycosphingolipids</subject><subject>Glycosphingolipids - deficiency</subject><subject>Glycosphingolipids - genetics</subject><subject>Immunity, Innate</subject><subject>Immunity, Innate - genetics</subject><subject>Interleukin-10</subject><subject>Interleukin-10 - antagonists & inhibitors</subject><subject>Interleukin-10 - biosynthesis</subject><subject>Interleukin-4</subject><subject>Interleukin-4 - antagonists & inhibitors</subject><subject>Interleukin-4 - biosynthesis</subject><subject>Leishmania major</subject><subject>Leishmania major - genetics</subject><subject>Leishmania major - immunology</subject><subject>Leishmania major - pathogenicity</subject><subject>Leishmaniasis, Cutaneous</subject><subject>Leishmaniasis, Cutaneous - genetics</subject><subject>Leishmaniasis, Cutaneous - immunology</subject><subject>Leishmaniasis, Cutaneous - prevention & control</subject><subject>Life Sciences</subject><subject>Membrane Proteins</subject><subject>Membrane Proteins - deficiency</subject><subject>Membrane Proteins - genetics</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Knockout</subject><subject>Mice, SCID</subject><subject>Protozoan Proteins</subject><subject>Protozoan Proteins - genetics</subject><subject>Protozoan Vaccines</subject><subject>Protozoan Vaccines - administration & dosage</subject><subject>Protozoan Vaccines - genetics</subject><subject>Protozoan Vaccines - immunology</subject><subject>Th1 Cells</subject><subject>Th1 Cells - immunology</subject><subject>Th1 Cells - metabolism</subject><subject>Th1 Cells - parasitology</subject><subject>Vaccines, Attenuated</subject><subject>Vaccines, Attenuated - administration & dosage</subject><subject>Vaccines, Attenuated - genetics</subject><subject>Vaccines, Attenuated - immunology</subject><subject>Virulence</subject><subject>Virulence - genetics</subject><subject>Virulence - immunology</subject><issn>0022-1767</issn><issn>1550-6606</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcuO0zAUhi0EYjoDT4CEvIJVim-xk-WowHSkIkbMMFvLdtzGVRIH2yHqo_C2uLRcdqzOWXz_uegD4BVGS4ZY_W7v-n4afLfEgiz5koqaPgELXJao4Bzxp2CBECEFFlxcgMsY9wghjgh7Di5wiRDDFVuAH4_KGDeo5PwAZ5daeNf6OLZ-1x2MGor3duuMs0OCG-ti26vBKdirvQ_wLvhkTYpw7XZtd4D3UzR2TE53Fn5yxsJt8D18dGHqjvlVq7rc7OyvNX5K8HZoprx7BxW8T8Hn5qHF8IuNox-ifQGebVUX7ctzvQJfP354WK2Lzeeb29X1pjCMiVQ0qtFC15xSpitsdFMrbuqGVIRR1ChFdV0hZTnWumzqUjCCK4FxWWlSKioYvQLFaW6-T47B9SocpFdOrq83clQx2SlIRDGqMam-48y_OfFj8N8mG5PsXX6869Rg_RSlwAJxRvh_QVwhWpKSZJCeQBN8jMFu_5yBkTyqlr9Vy6xacnlUnVOvz-Mn3dvmb-bsNgNvz49lP7MLVsY-K8g4lvM8_zPqJ-QMtxI</recordid><startdate>20040315</startdate><enddate>20040315</enddate><creator>Uzonna, Jude E</creator><creator>Spath, Gerald F</creator><creator>Beverley, Stephen M</creator><creator>Scott, Phillip</creator><general>Am Assoc Immnol</general><general>Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-0256-2029</orcidid></search><sort><creationdate>20040315</creationdate><title>Vaccination with Phosphoglycan-Deficient Leishmania major Protects Highly Susceptible Mice from Virulent Challenge without Inducing a Strong Th1 Response</title><author>Uzonna, Jude E ; Spath, Gerald F ; Beverley, Stephen M ; Scott, Phillip</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-dadb7b96334b81cbd9a6c9d282430daa3b980ae61bb5d957421871158b25a3743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Female</topic><topic>Genetic Predisposition to Disease</topic><topic>Glycosphingolipids</topic><topic>Glycosphingolipids - deficiency</topic><topic>Glycosphingolipids - genetics</topic><topic>Immunity, Innate</topic><topic>Immunity, Innate - genetics</topic><topic>Interleukin-10</topic><topic>Interleukin-10 - antagonists & inhibitors</topic><topic>Interleukin-10 - biosynthesis</topic><topic>Interleukin-4</topic><topic>Interleukin-4 - antagonists & inhibitors</topic><topic>Interleukin-4 - biosynthesis</topic><topic>Leishmania major</topic><topic>Leishmania major - genetics</topic><topic>Leishmania major - immunology</topic><topic>Leishmania major - pathogenicity</topic><topic>Leishmaniasis, Cutaneous</topic><topic>Leishmaniasis, Cutaneous - genetics</topic><topic>Leishmaniasis, Cutaneous - immunology</topic><topic>Leishmaniasis, Cutaneous - prevention & control</topic><topic>Life Sciences</topic><topic>Membrane Proteins</topic><topic>Membrane Proteins - deficiency</topic><topic>Membrane Proteins - genetics</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Knockout</topic><topic>Mice, SCID</topic><topic>Protozoan Proteins</topic><topic>Protozoan Proteins - genetics</topic><topic>Protozoan Vaccines</topic><topic>Protozoan Vaccines - administration & dosage</topic><topic>Protozoan Vaccines - genetics</topic><topic>Protozoan Vaccines - immunology</topic><topic>Th1 Cells</topic><topic>Th1 Cells - immunology</topic><topic>Th1 Cells - metabolism</topic><topic>Th1 Cells - parasitology</topic><topic>Vaccines, Attenuated</topic><topic>Vaccines, Attenuated - administration & dosage</topic><topic>Vaccines, Attenuated - genetics</topic><topic>Vaccines, Attenuated - immunology</topic><topic>Virulence</topic><topic>Virulence - genetics</topic><topic>Virulence - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Uzonna, Jude E</creatorcontrib><creatorcontrib>Spath, Gerald F</creatorcontrib><creatorcontrib>Beverley, Stephen M</creatorcontrib><creatorcontrib>Scott, Phillip</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>The Journal of immunology (1950)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Uzonna, Jude E</au><au>Spath, Gerald F</au><au>Beverley, Stephen M</au><au>Scott, Phillip</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccination with Phosphoglycan-Deficient Leishmania major Protects Highly Susceptible Mice from Virulent Challenge without Inducing a Strong Th1 Response</atitle><jtitle>The Journal of immunology (1950)</jtitle><addtitle>J Immunol</addtitle><date>2004-03-15</date><risdate>2004</risdate><volume>172</volume><issue>6</issue><spage>3793</spage><epage>3797</epage><pages>3793-3797</pages><issn>0022-1767</issn><eissn>1550-6606</eissn><abstract>Long-term immunity to Leishmania may require the continued presence of parasites, but previous attempts to create attenuated parasites that persist without causing disease have had limited success. Since Leishmania major mutants that lack lipophosphoglycan and other secreted phosphoglycans, termed lpg2-, persist indefinitely in infected mice without inducing any disease, we tested their ability to provide protection to virulent L. major challenge. In response to leishmanial Ag stimulation, cells from lpg2--infected mice produced minimal levels of IL-4 and IL-10, as well as very low levels of IFN-gamma. Nevertheless, when BALB/c mice infected with lpg2- parasites were challenged with virulent L. major they were protected from disease. Thus, these findings report on attenuated parasites that may be used to induce long-term protection against leishmaniasis and indicate that the immunity induced can be maintained in the absence of a strong Th1 response.</abstract><cop>United States</cop><pub>Am Assoc Immnol</pub><pmid>15004184</pmid><doi>10.4049/jimmunol.172.6.3793</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-0256-2029</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-1767 |
ispartof | The Journal of immunology (1950), 2004-03, Vol.172 (6), p.3793-3797 |
issn | 0022-1767 1550-6606 |
language | eng |
recordid | cdi_hal_primary_oai_HAL_pasteur_03109128v1 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Animals Female Genetic Predisposition to Disease Glycosphingolipids Glycosphingolipids - deficiency Glycosphingolipids - genetics Immunity, Innate Immunity, Innate - genetics Interleukin-10 Interleukin-10 - antagonists & inhibitors Interleukin-10 - biosynthesis Interleukin-4 Interleukin-4 - antagonists & inhibitors Interleukin-4 - biosynthesis Leishmania major Leishmania major - genetics Leishmania major - immunology Leishmania major - pathogenicity Leishmaniasis, Cutaneous Leishmaniasis, Cutaneous - genetics Leishmaniasis, Cutaneous - immunology Leishmaniasis, Cutaneous - prevention & control Life Sciences Membrane Proteins Membrane Proteins - deficiency Membrane Proteins - genetics Mice Mice, Inbred BALB C Mice, Inbred C57BL Mice, Knockout Mice, SCID Protozoan Proteins Protozoan Proteins - genetics Protozoan Vaccines Protozoan Vaccines - administration & dosage Protozoan Vaccines - genetics Protozoan Vaccines - immunology Th1 Cells Th1 Cells - immunology Th1 Cells - metabolism Th1 Cells - parasitology Vaccines, Attenuated Vaccines, Attenuated - administration & dosage Vaccines, Attenuated - genetics Vaccines, Attenuated - immunology Virulence Virulence - genetics Virulence - immunology |
title | Vaccination with Phosphoglycan-Deficient Leishmania major Protects Highly Susceptible Mice from Virulent Challenge without Inducing a Strong Th1 Response |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T11%3A59%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccination%20with%20Phosphoglycan-Deficient%20Leishmania%20major%20Protects%20Highly%20Susceptible%20Mice%20from%20Virulent%20Challenge%20without%20Inducing%20a%20Strong%20Th1%20Response&rft.jtitle=The%20Journal%20of%20immunology%20(1950)&rft.au=Uzonna,%20Jude%20E&rft.date=2004-03-15&rft.volume=172&rft.issue=6&rft.spage=3793&rft.epage=3797&rft.pages=3793-3797&rft.issn=0022-1767&rft.eissn=1550-6606&rft_id=info:doi/10.4049/jimmunol.172.6.3793&rft_dat=%3Cproquest_hal_p%3E18035252%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18035252&rft_id=info:pmid/15004184&rfr_iscdi=true |